

GAVI'S ENGAGEMENT IN POLIO ERADICATION

BOARD MEETING

Michael F Thomas, Stephen Sosler
6-7 June 2018, Geneva, Switzerland



Reach every child

www.gavi.org

Gavi's involvement in polio eradication

- **July 2005:** Board decision to provide time-limited support for mOPV stockpile
- **November 2013:** Board decision to support IPV introduction with policy waivers
 - **Dedicated funding:**
 - US\$ 430 million provided by GPEI donors (BMGF, DFID and Norway) for the period 2013-2019
 - **Policy exceptions:**
 - Co-financing
 - Eligibility
 - Transition policy
- **June 2017:** Board decision to continue IPV support through 2020 under same policy and funding conditions
- **June 2018:** Board to decide whether to support IPV through 2020 with core Gavi resources
- **December 2018:** Final Board decision on VIS investment case, including potential IPV support post-2020


Current polio situation and recent developments

Eradication progress

- 2018: 10 cases, 3 endemic countries
- Global certification no earlier than Q2 2021

IPV supply and price

- Improved supply in 2018, but remains fragile through 2020
- New vaccine tender – price increase of 60% - 140% for period 2019-2022*



SAGE recommendations

- 1 full or 2 fractional doses
- Catch-up vaccination of missed birth cohorts
- Move to 2-dose schedule

wP Hexavalent

- Progress made by some manufacturers on Hexavalent development
- Future Hexavalent scenarios to be incorporated into the VIS investment case

IPV support post-2020 (VIS)

Primary considerations




Funding levers

Country inclusion, eligibility	Country funding level	Funding duration	wP Hexavalent
<ul style="list-style-type: none"> • 70 countries (<i>status quo</i>) • Tailored based on risk • Standard eligibility + transition policy 	<ul style="list-style-type: none"> • Fully funded (<i>status quo</i>); • Tailored based on risk • Standard co-financing policy 	<ul style="list-style-type: none"> • 10 yrs from bOPV removal • Tailored based on risk • Standard eligibility + transition policy • Until certification 	<ul style="list-style-type: none"> • Primary series (i.e. pentavalent)

Programme factors

Year of certification	Supply	Dosing, vax schedule	Duration of use	Price
2021	Sufficient for 2 dose schedule	2 full or fractional doses	10 years	WAP informed by recent tender

IPV support post 2020 (VIS): trade-off between risks and cost



IPV support post 2020 (VIS): illustrative scenarios

Estimated costs to Gavi (in US\$ millions)

Scenarios	Description	2021-2025	2026-2032	Total
 Standard policies	<ul style="list-style-type: none"> Apply standard co-financing and eligibility policies 	650	450	1,100
 Tailored approach	<ul style="list-style-type: none"> Waive co-financing and eligibility policies for polio endemic, low income and preparatory transition countries Tailored co-financing for accelerated and fully self-financing countries 	800	800	1,600
 Status quo	<ul style="list-style-type: none"> Maintain current exceptional waivers on co-financing and eligibility Fully finance 70 countries 	900	1,200	2,100

Risk of programme discontinuation



Broader engagement in polio eradication:

Polio transition

Risk level	Countries
Endemic	Afghanistan, Nigeria, Pakistan
Very High	Chad, Somalia, South Sudan
High	DR Congo, Ethiopia, Sudan
Medium	Angola, Cameroon
Low	Bangladesh, India, Indonesia, Myanmar, Nepal, all low probability

- Limited risk to Gavi in most countries
- Six fragile countries considered high-risk
- JAs increasingly being leveraged to determine immunisation-critical functions and capacities for time-limited bridging support

Broader engagement in polio eradication:

Post Certification

Post-Certification Strategy (PCS) developed

WHO draft strategic action plan presented to WHA

Essential polio functions

	Part of current activities	Comparative advantage
• Strengthen immunization systems	✓	✓
• Ensure availability of affordable IPV	✓	✓
• Strengthened VPD surveillance and lab capacity	✓	✓
• Support for vaccine stockpiles (IPV and mOPVs)	---	✓
• Strategies for sustained IPV use and financing	---	✓
• Polio surveillance – AFP and environmental	---	---
• Containment of polioviruses	---	---
• Polio outbreak preparedness, detection and response	---	---

PPC recommendation to support IPV for 2019-2020

- **POB request primarily a consequence of the extension of the polio eradication timelines**
- **Global supply constraints have resulted in underspend (2013-2018) and additional costs for vaccination of missed cohorts 2019-2020**

Projected cost 2019-2020		US\$ 300 million
Secured IPV donor funds available	—	US\$ 100 million
Estimated incremental cost	=	US\$ 200 million

Recommendation

The Gavi Alliance Programme and Policy Committee recommends to the Gavi Alliance Board that it:

Approve the use of core resources for Gavi's support for inactivated poliovirus vaccine (IPV) for the period 2019-2020, noting that the financial implications associated with this approval are expected to be approximately US\$ 200 million.

THANK YOU



Reach every child

www.gavi.org